# G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

> **NCT00082329** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 9 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AMD 3100 (Mozobil plerixafor)
- **DRUG:** Granulocyte colony-stimulating factor (G-CSF)

## Key facts

- **NCT ID:** NCT00082329
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-18
- **Primary completion:** 2012-10-25
- **Final completion:** 2012-10-25
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082329, "G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00082329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*